Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esper...

FDA Recall #D-1143-2023 — Class III — August 16, 2023

Recall #D-1143-2023 Date: August 16, 2023 Classification: Class III Status: Completed

Product Description

Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108, NDC 72426-818-03

Reason for Recall

Failed dissolution specifications: below specification results at stability 12-month

Recalling Firm

Esperion — Ann Arbor, MI

Classification

Class III — Not likely to cause adverse health consequences.

Product Type

Drugs

Product Quantity

45,240 bottles

Distribution

Nationwide USA

Code Information

Lot# 1904872, Exp 1/31/2025; 1950377, Exp 6/30/2025

Status

Completed

Voluntary / Mandated

Voluntary: Firm initiated